Hyponatremia and antidiuresis syndrome

Annales d'Endocrinologie

Volumn 72, Issue 6, 2011, Pages 500-512

  Vantyghem, Marie Christine ^a   Balavoine, Anne Sophie ^a   Wémeau, Jean Louis ^a   Douillard, Claire ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AQUAPORIN 2; ARGIPRESSIN; CONIVAPTAN; CORTICOTROPIN; DEMECLOCYCLINE; FLUDROCORTISONE; INDOMETACIN; LIXIVAPTAN; MINERALOCORTICOID; PLACEBO; PROSTAGLANDIN INHIBITOR; SATAVAPTAN; SODIUM CHLORIDE; TOLVAPTAN; UREA; VASOPRESSIN; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ABSENCE OF SIDE EFFECTS; BLOOD VOLUME; BRAIN DISEASE; BRAIN EDEMA; CARBOHYDRATE METABOLISM; CORTICOTROPIN DEFICIENCY; CORTICOTROPIN RELEASE; DIFFERENTIAL DIAGNOSIS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DIURESIS; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG WITHDRAWAL; ELECTROLYTE BALANCE; EMERGENCY CARE; ENAMEL HYPOPLASIA; HEART FAILURE; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HORMONAL REGULATION; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOALDOSTERONISM; HYPONATREMIA; HYPOPHOSPHATEMIC RICKETS; HYPOTENSION; HYPOTHYROIDISM; HYPOVOLEMIA; IATROGENIC DISEASE; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER DISEASE; LUNG DISEASE; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MARATHON RUNNER; NEPHROTIC SYNDROME; NONHUMAN; ONSET AGE; OSMOREGULATION; PATHOPHYSIOLOGY; PLASMA OSMOLALITY; POLYDIPSIA; POLYURIA; PROGNOSIS; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; SHORT SURVEY; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM DEPLETION; STOMACH DISEASE; SURVIVAL TIME; TOOTH DISCOLORATION; URINE OSMOLALITY; VASOCONSTRICTION; VASOPRESSIN RELEASE; WATER DEPRIVATION; WATER INTOXICATION; WEIGHT REDUCTION;

DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME; MODELS, BIOLOGICAL; PREVALENCE; PROGNOSIS; WATER-ELECTROLYTE BALANCE;

EID: 83255176672     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2011.10.001     Document Type: Short Survey

References (77)

1. Hannon M.J., Thompson C.J. The syndrome of inappropriate antidiuretic hormone: prevalence, causes and consequences. Eur J Endocrinol 2010, 162(Suppl 1):S5-S12.
2. Schwartz W.B., Bennett W., Curelop S., Bartter F.C. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957, 23:529-542.
3. Zerbe R., Stropes L., Robertson G. Vasopressin function in the syndrome of inappropriate antidiuresis. Annu Rev Med 1980, 31:315-327.
4. Sajadieh A., Binici Z., Mouridsen M.R., Nielsen O.W., Hansen J.F., Haugaard S.B. Mild hyponatremia carries a poor prognosis in community subjects. Am J Med 2009, 122:679-686.
5. Gankam Kengne F., Andres C., Sattar L., Melot C., Decaux G. Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM 2008, 101:583-588.
6. Zilberberg M.D., Exuzides A., Spalding J., Foreman A., Jones a G., Colby C., et al. Hyponatremia and hospital outcomes among patients with pneumonia: a retrospective cohort study. BMC Pulm Med 2008, 8:16.
7. Sherlock M., O'sullivan E., Agha A., Behan L.A., Rawluk D., Brennan P.J., et al. The incidence and pathophysiology of hyponatraemia after subarachnoid haemorrhage. Clin Endocrinol (Oxf) 2006, 64:250-254.
8. Gill G., Huda B., Boyd A., Skagen K., Wile D., Watson I., et al. Characteristics and mortality of severe hyponatraemia - a hospital-based study. Clin Endocrinol (Oxf) 2006, 65:246-249.
9. Dewolfe A., Lopez B., Arcement L.M., Hebert K. Low serum sodium as a poor prognostic indicator for mortality in congestive heart failure patients. Clin Cardiol 2010, 33:E13-E17.
10. Novack V., Pencina M., Zahger D., Fuchs L., Nevzorov R., Jotkowitz A., et al. Routine laboratory results and thirty day and one-year mortality risk following hospitalization with acute decompensated heart failure. PLoS One 2010, 5:e12184.
11. Vaa B.E., Asrani S.K., Dunn W., Kamath P.S., Shah V. H. Influence of serum sodium on MELD-based survival prediction in alcoholic hepatitis. Mayo Clin Proc 2011, 86:37-42.
12. Moini M., Hoseini-Asl M.K., Taghavi S.A., Sagheb M.M., Nikeghbalian S., Salahi H.A., et al. Hyponatremia a valuable predictor of early mortality in patients with cirrhosis listed for liver transplantation. Clin Transplant 2011, 25:638-645.
13. Waikar S.S., Curhan G.C., Brunelli S.M. Mortality associated with low serum sodium concentration in maintenance hemodialysis. Am J Med 2011, 124:77-84.
14. Hoorn E.J., Lindemans J., Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant 2006, 21:70-76.
15. Waikar S.S., Mount D.B., Curhan G.C. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009, 122:857-865.
16. Moses a M., Miller J.L., Levine M.A. Two distinct pathophysiological mechanisms in congenital nephrogenic diabetes insipidus. J Clin Endocrinol Metab 1988, 66:1259-1264.
17. Sinke A.P., Caputo C., Tsaih S.W., Yuan R., Ren D., Deen P.M., et al. Genetic analysis of mouse strains with variable serum sodium concentrations identifies the Nalcn sodium channel as a novel player in osmoregulation. Physiol Genomics 2011, 43:265-270.
18. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011, 11:98-107.
19. Ropero a B., Soriano S., Tuduri E., Marroqui L., Tellez N., Gassner B., et al. The atrial natriuretic peptide and guanylyl cyclase-A system modulates pancreatic beta-cell function. Endocrinology 2010, 151:3665-3674.
20. Thorens B. Central control of glucose homeostasis: the brain - endocrine pancreas axis. Diabetes Metab 2010, 36(Suppl 3):S45-S49.
21. Wald R., Jaber B.L., Price L.L., Upadhyay A., Madias N.E. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med 2010, 170:294-302.
22. Decaux G. Is asymptomatic hyponatremia really asymptomatic?. Am J Med 2006, 119:S79-S82.
23. Schrier R.W., Gross P., Gheorghiade M., Berl T., Verbalis J.G., Czerwiec F.S., et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006, 355:2099-2112.
24. Verbalis J.G., Barsony J., Sugimura Y., Tian Y., Adams D.J., Carter E.A., et al. Hyponatremia-induced osteoporosis. J Bone Miner Res 2010, 25:554-563.
25. Vantyghem M.C., Hober C., Evrard A., Ghulam A., Lescut D., Racadot A., et al. Transient pseudo-hypoaldosteronism following resection of the ileum: normal level of lymphocytic aldosterone receptors outside the acute phase. J Endocrinol Invest 1999, 22:122-127.
26. Nakagawa I., Kurokawa S., Nakase H. Hyponatremia is predictable in patients with aneurysmal subarachnoid hemorrhage-clinical significance of serum atrial natriuretic peptide. Acta Neurochir (Wien) 2010, 152:2147-2152.
27. Emet M., Caner I., Cakir M., Aslan S., Cakir Z. Lightning injury may cause abrupt cerebral salt wasting syndrome. Am J Emerg Med 2010, 28(640):e641-e643.
28. Arimura K., Watanabe O., Nagado T. A spectrum of neurological diseases with anti-VGKC antibody. Rinsho Shinkeigaku 2007, 47:845-847.
29. Irani S.R., Alexander S., Waters P., Kleopa K.A., Pettingill P., Zuliani L., et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010, 133:2734-2748.
30. Momi J., Tang C.M., Abcar A.C., Kujubu D.A., Sim J.J. Hyponatremia-what is cerebral salt wasting?. Perm J 2010, 14:62-65.
31. Maesaka J.K., Imbriano L.J., Ali N.M., Ilamathi E. Is it cerebral or renal salt wasting?. Kidney Int 2009, 76:934-938.
32. Lenhard T., Grimm C., Ringleb P.A. Renal salt wasting as part of dysautonomia in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2011, 82:1051-1053.
33. Hubert E.L., Teissier R., Fernandes-Rosa F.L., Fay M., Rafestin-Oblin M.E., Jeunemaitre X., et al. Mineralocorticoid receptor mutations and a severe recessive pseudohypoaldosteronism Type 1. J Am Soc Nephrol 2011, 22:1997-2003.
34. Sasaki M., Yuzawa M., Saito T., Ikoma A., Tamemoto H., Kawakami M., et al. Clinical and laboratory features of hyponatremia-induced myopathy. Clin Exp Nephrol 2007, 11:283-286.
35. Ishikawa S., Saito T., Fukagawa A., Higashiyama M., Nakamura T., Kusaka I., et al. Close association of urinary excretion of aquaporin-2 with appropriate and inappropriate arginine vasopressin-dependent antidiuresis in hyponatremia in elderly subjects. J Clin Endocrinol Metab 2001, 86:1665-1671.
36. Pavone M.A., Solis Padrones A., Muratore D.G., Saiz M., Puig C. Hyponatraemia, hypopotassaemia and prerenal acute renal failure as a presentation of cystic fibrosis. Nefrologia 2010, 30:481-482.
37. Priou-Guesdon M., Malinge M.C., Augusto J.F., Rodien P., Subra J.F., Bonneau D., et al. Hypochloremia and hyponatremia as the initial presentation of cystic fibrosis in three adults. Ann Endocrinol (Paris) 2010, 71:46-50.
38. Feldshtein M., Elkrinawi S., Yerushalmi B., Marcus B., Vullo D., Romi H., et al. Hyperchlorhidrosis caused by homozygous mutation in CA12, encoding carbonic anhydrase XII. Am J Hum Genet 2010, 87:713-720.
39. Muhammad E., Leventhal N., Parvari G., Hanukoglu A., Hanukoglu I., Chalifa-Caspi V., et al. Autosomal recessive hyponatremia due to isolated salt wasting in sweat associated with a mutation in the active site of Carbonic Anhydrase 12. Hum Genet 2011, 129:397-405.
40. Boetzkes S., Van Hoeck K., Verbrugghe W., Ramet J., Wojciechowski M., Jorens P.G. Two unusual pediatric cases of dilutional hyponatremia. Pediatr Emerg Care 2010, 26:503-505.
41. Dunn A.L., Cox Gill J. Adenotonsillectomy in patients with desmopressin responsive mild bleeding disorders: a review of the literature. Haemophilia 2010, 16:711-716.
42. Brillouet-Banchereau A.C., Winnock S., Maurette P. Hyponatremic coma induced by desmopressin infusion in a woman with von Willebrand's disease. Ann Fr Anesth Reanim 2009, 28:909-910.
43. Sola E., Lens S., Guevara M., Martin-Llahi M., Fagundes C., Pereira G., et al. Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology 2010, 52:1783-1790.
44. Daveluy A., Raignoux C., Miremont-Salame G., Girodet P.O., Moore N., Haramburu F., et al. Drug interactions between inhaled corticosteroids and enzymatic inhibitors. Eur J Clin Pharmacol 2009, 65:743-745.
45. Jacob S., Spinler S.A. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. Ann Pharmacother 2006, 40:1618-1622.
46. Ellison D.H., Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007, 356:2064-2072.
47. Kim J.K., Summer S.N., Wood W.M., Schrier R.W. Osmotic and non-osmotic regulation of arginine vasopressin (AVP) release, mRNA, and promoter activity in small cell lung carcinoma (SCLC) cells. Mol Cell Endocrinol 1996, 123:179-186.
48. Decaux G. V2-antagonists for the treatment of hyponatraemia. Nephrol Dial Transplant 2007, 22:1853-1855.
49. Ranchin B., Boury-Jamot M., Blanchard G., Dubourg L., Hadj-Aissa A., Morin D., et al. Familial nephrogenic syndrome of inappropriate antidiuresis: dissociation between aquaporin-2 and vasopressin excretion. J Clin Endocrinol Metab 2010, 95:E37-E43.
50. Siegel A.J., Verbalis J.G., Clement S., Mendelson J.H., Mello N.K., Adner M., et al. Hyponatremia in marathon runners due to inappropriate arginine vasopressin secretion. Am J Med 2007, 461:e411-e467.
51. Hew-Butler T., Ayus J.C., Kipps C., Maughan R.J., Mettler S., Meeuwisse W.H., et al. Statement of the Second International Exercise-Associated Hyponatremia Consensus Development Conference, New Zealand, 2007. Clin J Sport Med 2008, 18:111-121.
52. Knechtle B., Knechtle P., Rosemann T. No exercise-associated hyponatremia found in an observational field study of male ultra-marathoners participating in a 24-hour ultra-run. Phys Sportsmed 2010, 38:94-100.
53. Fukunaka Y., Shinkai T., Hwang R., Hori H., Utsunomiya K., Sakata S., et al. The orexin 1 receptor (HCRTR1) gene as a susceptibility gene contributing to polydipsia-hyponatremia in schizophrenia. Neuromolecular Med 2007, 9:292-297.
54. Meerabux J., Iwayama Y., Sakurai T., Ohba H., Toyota T., Yamada K., et al. Association of an orexin 1 receptor 408Val variant with polydipsia-hyponatremia in schizophrenic subjects. Biol Psychiatry 2005, 58:401-407.
55. Mannesse C.K., Van Puijenbroek E.P., Jansen P.A., Van Marum R.J., Souverein P.C., Egberts T.C. Hyponatraemia as an adverse drug reaction of antipsychotic drugs: a case-control study in VigiBase. Drug Saf 2010, 33:569-578.
56. Yalcin-Cakmakli G., Karli Oguz K., Shorbagi A., Funda Bas D., Ergan-Arsava B., Kunt M., et al. Hyponatremic encephalopathy after excessive water ingestion prior to pelvic ultrasound: neuroimaging findings. Intern Med 2010, 49:1807-1811.
57. Gifford R.M. Seizures due to water loading in a young epileptic woman preparing for full bladder ultrasound. Clin Radiol 2011, 66:96.
58. Haris A., Demeter P., Toth I., Polner K. Severe hyponatremia and comatose state during colonoscopy preparation. Orv Hetil 2010, 151:828-831.
59. Darwish A.M., Hassan Z.Z., Attia A.M., Abdelraheem S.S., Ahmed Y.M. Biological effects of distension media in bipolar versus monopolar resectoscopic myomectomy: a randomized trial. J Obstet Gynaecol Res 2010, 36:810-817.
60. Indman P.D. Water should not be used for uterine distension. Am J Obstet Gynecol 2010, 202:e21-e22.
61. Gankam-Kengne F., Soupart A., Pochet R., Brion J.P., Decaux G. Minocycline protects against neurologic complications of rapid correction of hyponatremia. J Am Soc Nephrol 2011, 21:2099-2108.
62. De Troyer A. Demeclocycline. Treatment for syndrome of inappropriate antidiuretic hormone secretion. JAMA 1977, 237:2723-2726.
63. Perks W.H., Walters E.H., Tams I.P., Prowse K. Demeclocycline in the treatment of the syndrome of inappropriate secretion of antidiuretic hormone. Thorax 1979, 34:324-327.
64. Forrest J.N., Cox M., Hong C., Morrison G., Bia M., Singer I. Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 1978, 298:173-177.
65. Decaux G., Soupart A., Unger J., Delwiche F. Demeclocycline-induced phosphate diabetes in patients with inappropriate secretion of antidiuretic hormone. N Engl J Med 1985, 313:1480-1481.
66. Decaux G., Brimioulle S., Genette F., Mockel J. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea. Am J Med 1980, 69:99-106.
67. Eggleton M.G. The diuretic action of alcohol in man. J Physiol 1942, 101:172-191.
68. Ducobu J., Dupont P., Jonckheer J. Inappropriate secretion of ADH corrected by ethanol in tuberculous meningitis. Lancet 1981, 1:214-215.
69. Ducobu J., Dupont P. Inhibition of prostaglandins in the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Presse Med 1983, 12:1279-1282.
70. Cohen M.H., Bunn P.A., Ihde D.C., Fossieck B.E., Minna J.D. Chemotherapy rather than demeclocycline for inappropriate secretion of antidiuretic hormone. N Engl J Med 1978, 298:1423-1424.
71. Ghali J.K., Koren M.J., Taylor J.R., Brooks-Asplund E., Fan K., Long W.A., et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006, 91:2145-2152.
72. Finley J.J., Konstam M.A., Udelson J.E. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 2008, 118:410-421.
73. Gheorghiade M., Niazi I., Ouyang J., Czerwiec F., Kambayashi J., Zampino M., et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double blind, randomized trial. Circulation 2003, 107:2690-2696.
74. Gheorghiade M., Konstam M.A., Burnett J.C., Grinfeld L., Maggioni A.P., Swedberg K., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007, 297:1332-1343.
75. Aronson D., Verbalis J.G., Mueller M., Krum H. Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study. Eur J Heart Fail 2011, 13:327-336. DILIPO investigators.
76. Gerbes A.L., Gülberg V., Ginès P., Decaux G., Gross P., Gandjini H., et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double blind multicenter trial. Gastroenterology 2003, 124:933-939.
77. Yamaguchi K., Shijubo N., Kodama T., Mori K., Sugiura T., Kuriyama T., et al. Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome. Jpn J Clin Oncol 2011, 41:148-152.